Ymera Pignochino

A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study

Giovanni Grignani, Emanuela Palmerini, Palma Dileo et al. · Annals of Oncology · 2011 · 353 citations · Full text

Surgical Oncology, Phase Ii Trial, Medicine +7

Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial

Giovanni Grignani, Emanuela Palmerini, Virginia Ferraresi et al. · The Lancet Oncology · 2014 · 328 citations · Full text

Surgical Oncology, Medicine, Standard Treatment +6

Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways

Ymera Pignochino, Giovanni Grignani, Giuliana Cavalloni et al. · Molecular Cancer · 2009 · 175 citations · Full text

Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas

Ymera Pignochino, Ivana Sarotto, Caterina Peraldo‐Neia et al. · BMC Cancer · 2010 · 172 citations · Full text

Somatic Mutations of Epidermal Growth Factor Receptor in Bile Duct and Gallbladder Carcinoma

Francesco Leone, Giuliana Cavalloni, Ymera Pignochino et al. · Clinical Cancer Research · 2006 · 169 citations